(HealthDay News) — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback